<DOC>
	<DOCNO>NCT01484977</DOCNO>
	<brief_summary>The main purpose study evaluate effectiveness study drug lacosamide ( 200-600 mg/day ) add stable dose levetiracetam ( 1000-3000 mg/day ) withdrawal concomitant sodium channel blocking-antiepileptic drug ( AEDs ) subject well control current regimen .</brief_summary>
	<brief_title>eValuation Efficacy toleRability Vimpat When Added lEvetiracetam</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subject male female , least 18 year age Subject diagnosis epilepsy partialonset seizures accord International Classification Epileptic Seizures ( 1981 ) Subject take levetiracetam ( LEV ) combination 1 sodium channel block antiepileptic drug ( defined carbamazepine , lamotrigine , oxcarbazepine , phenytoin , eslicarbazepine ) adjunctive treatment epilepsy The minimum required seizure frequency 8week Retrospective Seizure Baseline average ≥ 2 partialonset seizure per 28 day least 1 seizure per 4 week period within 8week Retrospective Seizure Baseline . Additionally , subject must experience least 1 seizure 4week Prospective Seizure Baseline Subject maintain stable dose LEV sodium channel block antiepileptic drug ( SCBAED ) least 4 week prior Screening Visit ( Visit 1 ) 4week Prospective Seizure Baseline The minimum required seizure frequency 8week Retrospective Seizure Baseline average ≥ 2 partialonset seizure per 28 day ( base investigator assessment subject report ) least 1 seizure per 4 week period within 8week Retrospective Seizure Baseline Subject maintain stable dose levetiracetam ( LEV ) sodium channel block antiepileptic drug ( SCBAED ) least 4 week prior Screening Visit ( Visit 1 ) 4week Prospective Seizure Baseline , without additional concurrent stable vagal nerve stimulation ( VNS ) . The VNS must place least 6 month prior Screening Visit ( Visit 1 ) constant setting least 4weeks prior Screening Visit ( Visit 1 ) throughout duration study Previous use lacosamide History alcohol drug abuse History seizure disorder characterize primarily isolate auras History primary generalize seizure History status epilepticus within 12months History clustering seizures Nonepileptic event , include pseudoseizures could confuse seizure History medical psychiatric condition , opinion investigator , could jeopardize subject 's health would compromise subject 's ability participate study Lifetime history suicide attempt , suicidal ideation past 6 month Hypersensitivity component lacosamide ( LCM ) History acute subacute progressive central nervous system disease History severe anaphylactic reaction serious blood dyscrasia Impaired renal function ( ie , Creatinine Clearance ( CLcr ) low 30 mL/min ) Visit 1 History sick sinus syndrome without pacemaker , atrioventricular ( AV ) block , subject clinically significant electrocardiogram ( ECG ) abnormalities History sodium channelopathy , Brugada syndrome History myocardial infarction last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Levetiracetam</keyword>
	<keyword>Sodium Channel Blockers</keyword>
</DOC>